VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Remaining hurdles in liquid biopsies

Susanne Flach • 6 Jun 2022
ASCO 2022
Head and Neck Cancer
Molecular Profiling

Susanne Flach, BM BCh, PhD, Ludwig-Maximilians-University, Munich, Germany, reflects on the use of circulating tumor DNA (ctDNA) approaches in head and neck squamous cell carcinoma, highlighting the importance of improving sensitivty, reducing cost of next-generation sequencing and standardization of techniques. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Susanne Flach

5:37
LIONESS: a personalized cell-free tumor DNA analysis for patients with HNSCC.
Susanne Flach • 6 Jun 2022

Related Videos

3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
2:00
Durvalumab plus danvatirsen for R/M HNSCC: exciting SCORES data
Ezra Cohen
3:10
The risks of radioactive iodine treatment in thyroid cancer
Remco Molenaar
0:58
Checkpoint inhibitors for head and neck cancer in the definitive setting?
Barbara Burtness
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals